Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVB-006
- Development stage
- Discontinued
- Lead developer
- Avenge Bio
- Modality
- Other Cell Types → Cell Therapies
01
Overview
AVB-006 is a discontinued allogeneic encapsulated cell therapy developed by Avenge Bio using the proprietary LOCOcyte™ platform. The LOCOcyte™ technology involves the local administration of engineered, encapsulated cells designed to provide sustained, high-concentration delivery of therapeutic payloads directly to the tumor microenvironment. This approach aims to maximize the therapeutic effect of potent immune-modulators while minimizing systemic exposure and associated toxicities. Although the specific payload for AVB-006 was not publicly disclosed, the platform generally focuses on immunomodulatory proteins for the treatment of solid tumors.
- Other names
- LOCOcyte (unspecified payload)
Beyond the preview
Go deeper on AVB-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVB-006.